Dual Targeting of ROR1 and BTK Augments the Anti-Lymphoma Activity in Mantle Cell Lymphoma

套细胞淋巴瘤 布鲁顿酪氨酸激酶 癌症研究 淋巴瘤 医学 生物 免疫学 酪氨酸激酶 内科学 受体
作者
Lei Nie,Changying Jiang,Yang Liu,Joseph McIntosh,Jovanny Vargas,Qingsong Cai,Michael L. Wang
出处
期刊:Blood [American Society of Hematology]
卷期号:142 (Supplement 1): 4366-4366
标识
DOI:10.1182/blood-2023-189531
摘要

Background Mantle cell lymphoma (MCL) is a rare and aggressive subtype of non-Hodgkin lymphoma. Development of BTK inhibitors (BTKis) and CAR-T cells revolutionized the treatment paradigm for the patients with MCL. However, this aggressive B-cell lymphoma frequently relapses leading to poor survival. Therefore, novel therapies are in urgent need to overcome the therapeutic resistance. ROR1 is normally expressed during embryonic development but is usually absent or expressed at low levels in adult tissues. However, re-expression of ROR1 was found in various types of cancer, especially in cancer stem/tumor-initiating cells. ROR1 persistently activates oncogenic signaling pathways in the BCR/BTK-independent manner. Accordingly, we hypothesize that dual targeting of ROR1 and BTK may augment the therapeutic efficacy, and thus combination of monoclonal antibody zilovertamab (cirmtuzumab) targeting ROR1, and BTKis will overcome the therapeutic resistance and effectively kill the relapsed/refractory MCL cells. Methods A panel of MCL cell lines and primary patient samples were used in this study. ROR1 expression levels in MCL cell lines and primary MCL samples were determined by flow cytometry and western blotting. For establishment of patient-derived organoid (PDO), the patient samples or MCL cell from PDX tumors were resuspended in culture medium containing cytokine cocktails. The cell aggregates within 50% Matrigel were gently transferred into multiple-well plates as needed. The established PDOs were applied for drug sensitivity assays. In addition, a patient-derived xenograft (PDX) mouse model was also used for evaluating single agent and combination efficacy of BTKis and zilovertamab (Zilo). Cell viability assays were performed using CellTiter routine or 3D cell viability assay kit (Promega). Results We hypothesize dual targeting of both BTK and ROR1 signaling pathways will augment cytotoxic effect on the MCL cells including major proliferative and minor ROR1 +CD117 + population, whose survival is not dependent on BTK, in tumor mass. To test the hypothesis, we first analyzed the ROR1 expression in MCL cell lines, primary and PDX MCL cells using flow cytometry and immunoblotting analysis. Our results indicated that in comparison with normal PBMC, ROR1 expression were detected in all examined MCL cell lines including JeKo-1, Mino, Z-138, Granta519, JVM2, SP49, Maver-1 and Rec-1. To test whether p53 status relates to sensitivity of MCL cells to BTKi and Zilo, we examined cytotoxic effect of combination of BTKi and Zilo on MCL cell lines (1) harboring mutated TP53 (T P53 Mut): JeKo-1, JeKo-R, Mino, and Mino-R and (2) harboring wild-type TP53 ( TP53 WT): Z-138 and Maver-1, and PDO as well as PDX tumors derived from biopsies bearing either TP53 WT or TP53 Mut. Treatment with single BTKi at 2-10 µM (Ibrutinib, zanubrutinib, acalabrutinib or pirtobrutinib) significantly induced cytotoxicity in the TP53 MutMCL cells, and the cell death was remarkedly increased when BTKi was combined with Zilo at 25-50 µg/ml. In contrast, in MCL cell lines with TP53 WT, BTKi-Zilo combination did not significantly result in increase of cytotoxic effect compared to single agents. These results suggest that the genetic status of TP53 is important for the augmented cytotoxic effect of BTKi-Zilo combination on MCL cells. To further evaluate potentiated effect of BTKi-Zilo combination, we performed ex vivo viability assay using PDO platform. Typically, PDOs were treated with either single agent or combined regimens. Consistent with the data in MCL cell lines, BTKi-Zilo combination resulted in potentiated cytotoxic activity in the PDO models derived from naïve and relapsed patients harboring TP53 Mut. Furthermore, BTKi-Zilo combination displayed synergistic effect in a PDX model derived from a patient harboring TP53 Mut. Conclusion Dual targeting of BTK and ROR1 signaling pathways augmented efficacy selectively in preclinical MCL models with TP53 Mut. These data provide insights to develop tailored therapeutics to improve patient outcome for patients with TP53 mutation.

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
MEMSforever发布了新的文献求助30
1秒前
酷波er应助吱吱采纳,获得10
6秒前
小鱼小鱼快快游完成签到 ,获得积分10
8秒前
蜜蜂威士忌完成签到 ,获得积分10
12秒前
bai1完成签到 ,获得积分10
18秒前
爆米花应助wowser采纳,获得10
18秒前
陈麦子完成签到,获得积分10
19秒前
小杨完成签到 ,获得积分10
22秒前
852应助水盒子采纳,获得10
23秒前
薰硝壤应助科研通管家采纳,获得10
27秒前
可爱香芦完成签到 ,获得积分10
34秒前
黑大侠完成签到 ,获得积分10
43秒前
璇璇完成签到 ,获得积分10
44秒前
50秒前
nano完成签到 ,获得积分10
52秒前
慕容飞凤完成签到,获得积分10
52秒前
勤奋千风完成签到 ,获得积分10
55秒前
philophysics完成签到,获得积分10
58秒前
Jaja完成签到,获得积分10
1分钟前
wushuimei完成签到 ,获得积分10
1分钟前
tt完成签到 ,获得积分10
1分钟前
1分钟前
Tim完成签到 ,获得积分10
1分钟前
Oct完成签到 ,获得积分10
1分钟前
1分钟前
皮皮球完成签到 ,获得积分10
1分钟前
黄金天下完成签到,获得积分10
1分钟前
北城完成签到 ,获得积分10
1分钟前
llhh2024完成签到,获得积分10
1分钟前
水盒子完成签到,获得积分10
1分钟前
i2stay完成签到,获得积分10
1分钟前
nt1119完成签到 ,获得积分10
1分钟前
成就的绮烟完成签到 ,获得积分10
1分钟前
月潮共生完成签到 ,获得积分10
1分钟前
果果完成签到,获得积分10
1分钟前
细心的代天完成签到 ,获得积分10
1分钟前
lululululululu完成签到 ,获得积分10
1分钟前
jxas完成签到,获得积分10
1分钟前
洁净青筠发布了新的文献求助10
1分钟前
Ethan完成签到 ,获得积分10
1分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052652
求助须知:如何正确求助?哪些是违规求助? 2709874
关于积分的说明 7418298
捐赠科研通 2354492
什么是DOI,文献DOI怎么找? 1246104
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921